Publications
Filters: First Letter Of Keyword is C [Clear All Filters]
Mapping eQTL by leveraging multiple tissues and DNA methylation." BMC Bioinformatics 18, no. 1 (2017): 455.
"Mapping eQTL by leveraging multiple tissues and DNA methylation." BMC Bioinformatics 18, no. 1 (2017): 455.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective." Lifetime Data Anal 23, no. 4 (2017): 585-604.
"Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
"Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective." Lifetime Data Anal 23, no. 4 (2017): 585-604.
"Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective." Lifetime Data Anal 23, no. 4 (2017): 585-604.
"Improved detection of epigenomic marks with mixed-effects hidden Markov models." Biometrics 75, no. 4 (2019): 1401-1413.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Parameter estimation in Cox models with missing failure indicators and the OPPERA study." Stat Med 34, no. 30 (2015): 3984-96.
"Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008." BMC Med Res Methodol 19, no. 1 (2019): 2.
"Parameter estimation in Cox models with missing failure indicators and the OPPERA study." Stat Med 34, no. 30 (2015): 3984-96.
"Association test using Copy Number Profile Curves (CONCUR) enhances power in rare copy number variant analysis." PLoS Comput Biol 16, no. 5 (2020): e1007797.
"Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics." Respir Res 19, no. 1 (2018): 152.
"Time-varying latent effect model for longitudinal data with informative observation times." Biometrics 68, no. 4 (2012): 1093-102.
"Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51.
"Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Medical records-based postmarketing safety evaluation of rare events with uncertain status." J Biopharm Stat 23, no. 4 (2013): 744-55.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme." Biometrics 69, no. 3 (2013): 714-23.
"Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme." Biometrics 69, no. 3 (2013): 714-23.
"A smoothing-based goodness-of-fit test of covariance for functional data." Biometrics 75, no. 2 (2019): 562-571.
"Checking semiparametric transformation models with censored data." Biostatistics 13, no. 1 (2012): 18-31.
"Semiparametric additive marginal regression models for multiple type recurrent events." Lifetime Data Anal 18, no. 4 (2012): 504-27.
"Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76.
"Bayesian design of noninferiority trials for medical devices using historical data." Biometrics 67, no. 3 (2011): 1163-70.
"Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome." Biometrics 70, no. 4 (2014): 1003-13.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"Checking semiparametric transformation models with censored data." Biostatistics 13, no. 1 (2012): 18-31.
"More insights into early brain development through statistical analyses of eigen-structural elements of diffusion tensor imaging using multivariate adaptive regression splines." Brain Struct Funct 219, no. 2 (2014): 551-69.
"Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs." Stat Med 31, no. 28 (2012): 3597-616.
"Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76.
"Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration." Biometrics 71, no. 4 (2015): 918-28.
"Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome." Biometrics 70, no. 4 (2014): 1003-13.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses." J Biopharm Stat 24, no. 4 (2014): 817-33.
"Longitudinal regression analysis of spatial-temporal growth patterns of geometrical diffusion measures in early postnatal brain development with diffusion tensor imaging." Neuroimage 58, no. 4 (2011): 993-1005.
"Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs." Stat Med 31, no. 28 (2012): 3597-616.
"Simulation of brain mass effect with an arbitrary Lagrangian and Eulerian FEM." Med Image Comput Comput Assist Interv 13, no. Pt 2 (2010): 274-81.
"A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews." Stat Methods Med Res 26, no. 2 (2017): 914-930.
"Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79.
"Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.
"Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation." Stat Methods Med Res 24, no. 6 (2015): 836-55.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"Biclustering with heterogeneous variance." Proc Natl Acad Sci U S A 110, no. 30 (2013): 12253-8.
"A simple and robust method for multivariate meta-analysis of diagnostic test accuracy." Stat Med 36, no. 1 (2017): 105-121.
"Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
"Bayesian modeling and inference for clinical trials with partial retrieved data following dropout." Stat Med 32, no. 24 (2013): 4180-95.
"Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study." Lifetime Data Anal 26, no. 4 (2020): 685-707.
"Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation." Stat Methods Med Res 24, no. 6 (2015): 836-55.
"Bayesian design of noninferiority trials for medical devices using historical data." Biometrics 67, no. 3 (2011): 1163-70.
"Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Joint modeling of survival time and longitudinal outcomes with flexible random effects." Lifetime Data Anal 24, no. 1 (2018): 126-152.
"Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy." Clin Pharmacol Ther 108, no. 3 (2020): 625-634.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Efficient methods for signal detection from correlated adverse events in clinical trials." Biometrics 75, no. 3 (2019): 1000-1008.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Efficient methods for signal detection from correlated adverse events in clinical trials." Biometrics 75, no. 3 (2019): 1000-1008.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"Ascertaining properties of weighting in the estimation of optimal treatment regimes under monotone missingness." Stat Med 39, no. 25 (2020): 3503-3520.
"Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
"Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
"Semiparametric estimation of the accelerated failure time model with partly interval-censored data." Biometrics 73, no. 4 (2017): 1161-1168.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
"On optimal treatment regimes selection for mean survival time." Stat Med 34, no. 7 (2015): 1169-84.
"On optimal treatment regimes selection for mean survival time." Stat Med 34, no. 7 (2015): 1169-84.
"Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'." Stat Med 34, no. 14 (2015): 2202-3.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"Bayesian lasso for semiparametric structural equation models." Biometrics 68, no. 2 (2012): 567-77.
"Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation." Biometrics 70, no. 3 (2014): 765-73.
"Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation." Biometrics 70, no. 3 (2014): 765-73.
"Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
" " "